A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies

Simultaneously targeting other pathways could increase the activity of PD-1 blockade in lymphoid malignancies not sensitive to single-agent blockade. We explored the safety and efficacy of combined PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory (R/R) lymphoid malignancies. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Armand, Philippe, Lesokhin, Alexander, Borrello, Ivan, Timmerman, John, Gutierrez, Martin, Zhu, Lili, Popa McKiver, Mihaela, Ansell, Stephen M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932914/
https://www.ncbi.nlm.nih.gov/pubmed/32601377
http://dx.doi.org/10.1038/s41375-020-0939-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932914/
https://www.ncbi.nlm.nih.gov/pubmed/32601377
http://dx.doi.org/10.1038/s41375-020-0939-1

Ejemplares similares